Advertisment

Comparing Laser Combination Therapy and Ranibizumab Monotherapy for Diabetic Macular Edema: An Insightful Study

author-image
Ethan Sulliva
New Update
NULL

Comparing Laser Combination Therapy and Ranibizumab Monotherapy for Diabetic Macular Edema: An Insightful Study

Advertisment

Understanding the effectiveness of various treatment methods for diabetic macular edema (DME) is essential for both patients and healthcare providers. In a recent study, researchers compared the visual outcomes of laser combination therapy and Ranibizumab monotherapy for DME. The study involved 100 eyes, with 76 eyes analyzed. It is worth noting that both treatment groups showed similar baseline characteristics.

Advertisment

Visual Acuity Improvements

The study revealed that the mean improvement in visual acuity was 3.2 letters in the laser combination group. However, there was a decline of 7.5 letters in the Ranibizumab group. Despite this difference, statistical analysis indicated no significant difference between the two groups. This finding suggests that both therapies may offer comparable benefits in terms of improving visual acuity in DME patients.

Macular Thickness and Intravitreal Treatments

Advertisment

The study also measured macular thickness improvement and the number of intravitreal treatments (IVTs) in both groups. Similar to the visual acuity results, there were no significant differences observed between the two groups. This result further supports the notion that both treatment methods may have similar efficacy levels.

Adverse Events

Adverse events during the study were rare. Only two significant incidents were reported: one case of cerebral infarction and one death from pneumonia. These unfortunate events underscore the importance of careful monitoring and follow-up during DME treatment.

Advertisment

Real-World Implications

A retrospective real-world study conducted in Türkiye corroborates these findings. This study included 1,372 eyes of 854 patients treated with a pro-re nata protocol by 21 ophthalmologists. Despite showing inferior best-corrected visual acuity (BCVA) gains compared to randomized controlled trials, the study demonstrated relatively superior gains compared to other real-life study counterparts. This was primarily due to the lower baseline BCVA and higher intravitreal dexamethasone implant (IDI) combination rates in the cohorts.

Additional Insights

Another source provides further insights into the effectiveness of combined therapy for treating DME. It discusses the regression of neovascularization after panretinal photocoagulation combined with anti-VEGF injection for proliferative diabetic retinopathy. The combination therapy's effectiveness underlines the potential of combined therapy in treating DME.

In conclusion, both laser combination therapy and Ranibizumab monotherapy offer potential benefits for DME patients. While the study shows no significant difference in visual acuity improvement, macular thickness improvement, or the number of IVTs, it is critical to consider individual patient conditions and potential adverse events when deciding on a treatment plan.

Advertisment
Chat with Dr. Medriva !